You may also like
ZymoGenetics Submits Citizen Petition to FDA Requesting Removal of Bovine Thrombin from Market in the Interest of Patient Safety
ZymoGenetics, Inc. (NASDAQ:ZGEN), announced today the submission of a Citizen Petition to the U.S. Food and Drug Administration (FDA) requesting that the FDA remove Thrombin-JMI® Thrombin, topical (bovine origin) from the market in the interest of patient safety. The Citizen Petition is prompted by recent reports of serious or fatal bleeding-related adverse events in surgical patients exposed to bovine (cattle-derived) thrombin.
3 min read
Evaluation and Reconditioning of Donor Organs for Transplantation Through Ex Vivo Lung Perfusion
In this prospective study, we subjected five lungs considered to be high risk for transplantation to 4 hours of ex vivo lungperfusion, with evaluation of oxygenation capacity.
1 min read